|
|
Home > Recent Advances in Development of Multi-Kinase Inh
| | |
|
Blog - Recent Advances in the Development of Multi-Kinase Inhibitors
|
Last Updated November 8, 2008
|
|
|
During the last two decades, protein kinases have emerged as a major target for cancer therapy and a large number of selective kinase inhibitors have been developed as potential anticancer drugs. To avoid unpredictable toxic effects, researchers usually aim at designing highly selective inhibitors. But since the formation and progression of a tumor has to be considered as a multifactorial process, which is dependent on different signaling pathways, it seems reasonable to establish anticancer therapies that target several kinases concomitantly using a combination of a set of selective kinase inhibitors or by administering a single agent, which simultaneously inhibits several kinases, a so called multi-kinase inhibitor. In this review, benefits and obstacles of both strategies are discussed. An overview over recently approved and newly upcoming multi-kinase inhibitors is given.
|
|
Posted by M. Krug and A. Hilgeroth on November 8, 2008
|
| Comments 0 of 0
|
|
|
|
If you would like to comment on this post, please fill out the form below.
|
* denotes required field
Post Your Comments On*
Comment*
99999 characters remaining
|
| *All comments will undergo a review process before they are posted online. This is to prevent spam and ads from being posted. Thank you for your time and patience.
|
|
Opinions expressed on the ACC Corporation Blog and all corresponding comments are the individual opinions of the original authors and don’t in any way reflect the opinions of ACC Corporation.
|
|
| |
| |
| | |
|
You must be logged in to view your shopping cart information
We accept all major credit cards
We have clients in over
75 countries spanning 5
continents
Advertise with American Custom Chemical Corporations. We make it beneficial and profitable for you to work with us.
To track your order please click on the shipping options below
For the latest updates on industry information and news
|
|